Skip to content

Embecta Corp. EMBC Free cash flow margin

Free cash flow margin at other companies

Insulet logo
InsuletPODD
14.3%+1.1pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-0.8%-0.4pp
Medtronic logo
MedtronicMDT
14.9%-0.5pp
Mannkind logo
MannkindMNKD
13.8%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
-55.4%-14.3pp
ICU Medical logo
ICU MedicalICUI
4.2%-1.2pp

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Calculated from Embecta Corp.’s reported figures.

Based on trailing twelve months.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s free cash flow margin?
Embecta Corp. (EMBC) reported free cash flow margin of 19.6% in Q1 2026.
How has Embecta Corp.'s free cash flow margin changed year-over-year?
Embecta Corp.'s free cash flow margin increased by 433.9% year-over-year, from 3.7% to 19.6%.
What is the long-term trend for Embecta Corp.'s free cash flow margin?
Over 3 years (2021 to 2025), Embecta Corp.'s free cash flow margin has grown at a -22.3% compound annual growth rate (CAGR), from 36% to 16.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.